 NEW YORK, Dec. 02, 2020 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration FDA has granted Fast Track designation for remestemcel-L in the treatment of acute respiratory distress syndrome ARDS due to COVID-19 infection. Fast Track designation is granted if a therapy demonstrates the potential to address unmet medical needs for a serious or life-threatening disease.1 ARDS is the primary cause of death in patients with COVID-19. 